Summary
In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate variation to standard stimuli) in eight parkinsonian patients.
Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h·ng·ml−1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h. The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h·μg·ml−1 by entacapone. A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h·ng·ml−1). Entacapone also decreased the excretion of HVA but not that of 3-methoxytyramine in the urine.
Cardiovascular autonomic responses to sympathetic and parasympathetic stimuli were not changed by entacapone.
We conclude that a single dose of entacapone moderately increases the AUC and prolongs the t1/2el of levodopa in man and that that does not affect cardiovascular autonomic regulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Lindén I-B, Männistö PT, Kaakkola S, Pohto P (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase (COMT) inhibitors. J Med Chem 32: 841–846
Bannister R (ed) (1992) Autonomic failure. A textbook of clinical disorders of the autonomic nervous system, 3rd edn. Oxford Medical Publications, Oxford
Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives-synthesis and structure activity studies. Helv Chim Acta 72: 952–968
Calne DB, Reid JL, Vakil SD (1972) Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 14: 386–389
Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13: 141–178
Cedarbaum JM, Leger G, Guttman M (1991) Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomologus monkeys: Implications for the treatment of Parkson's disease. Clin Neuropharmacol 14: 330–342
Etemadzadeh E, Koskinen L, Kaakkola S (1989) Computerized rotometer apparatus for recording circling behaviour. Meth Find Exp Clin Pharmacol 11: 399–407
Gancher T, Nutt JG, Woodward WR (1987) Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients. Neurology 37: 940–944
Gervas J, Muradas B, Bazan E, Aguado E, de Yebenes J (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282
Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd edition. Dekker, New York
Gomeni C, Gomeni R (1987) IGPHARM: Iterative graphic package for pharmacokinetic analysis. Comp Biochem Res 11: 345–361
Gordin A, Sundberg S, Scheinin M, Keränen T (1992) Inhibition of catechol-O-methyltranseferase activity with entacapone does not affect hemodynamics or plasma catecholamine levels during exercise. Neurology 42 [Suppl 3]: 324
Jones B, Kenward M (1989) Design and analysis of cross-over trials. Chapman and Hall, London
Kaakkola S, Gordin A, Järvinen M, Wikberg T, Schultz E, Nissinen E, Pentikäinen PJ, Rita H (1990) Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol 13: 436–447
Karlsson M, Wikberg T (1992) Liquid chromatographic determination of a new catechol-O-methyl-transferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 10: 593–600
Keränen T, Gordin A, Harjola V-P, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145–156
Koch CG (1972) The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577–584
Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66: 317–323
Nissinen E, Lindén I-B, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346: 262–266
Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 21: 584–588
Reches A, Fahn S (1982) 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267–271
Reches A, Miekle L, Fahn S (1982) 3-O-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887–888
Robertson DRC, Renwick AG, Wood ND, Cross N, Macklin BS, Fleming JS, Waller DG, George CF (1990) The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 29: 47–53
Turkka JT, Tolonen U, Myllylä VV (1987) Cardiovascular reflexes in Parkinson's disease. Eur Neurol 26: 104–112
Wade L, Katzman R (1975) 3-O-methyldopa inhibition of L-dopa at the blood-brain barrier. Life Sci 17: 131–136
Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S, Von Sprecher G (1990) CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol 342: 305–311
Wikberg T (1991) Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 9: 167–176
Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1990) Ro-40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase — a pharmacological study in rats. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol. 53. Anatomy, pathology and therapy. Raven Press, New York, pp 497–503
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Myllylä, V.V., Sotaniemi, K.A., Illi, A. et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45, 419–423 (1993). https://doi.org/10.1007/BF00315512
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315512